Related Experiment Video
Updated: Jun 11, 2026
06:38
Droplet Digital TRAP (ddTRAP): Adaptation of the Telomere Repeat Amplification Protocol to Droplet Digital Polymerase Chain Reaction
Published on: May 3, 2019
Elevated TRF2 in advanced breast cancers with short telomeres
Malissa C Diehl1, Michael O Idowu, Katherine N Kimmelshue
1Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Breast Cancer Research and Treatment
|July 14, 2010
Summary
Telomere repeat binding factor 2 (TRF2) protein levels generally decrease with breast cancer progression. However, higher TRF2 expression in advanced cancers may protect cells with critically short telomeres.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Telomere repeat binding factor 2 (TRF2) is crucial for telomere maintenance and chromosomal stability.
- In vitro studies suggest increased TRF2 expression during mammary cancer, but clinical data on TRF2 protein levels remain limited.
Purpose of the Study:
- To investigate TRF2 protein levels and cellular localization in normal, pre-malignant, and malignant breast tissues.
- To correlate TRF2 expression with telomere length and clinical staging in breast cancer.
Main Methods:
- Utilized breast tissue arrays with normal, DCIS, and invasive carcinoma specimens.
- Assessed TRF2 protein expression and localization via immunohistochemistry.
- Measured telomere lengths using a pantelomeric probe.
- Employed mixed effects modeling for statistical analysis.
Main Results:
- TRF2 protein was exclusively nuclear, showing a trend toward lower expression with increased malignancy.
- Invasive carcinomas exhibited variable TRF2 expression and telomere lengths; normal tissues had longer telomeres.
- Higher TRF2 expression in invasive carcinomas correlated with shorter telomeres and advanced TNM stage.
Conclusions:
- Elevated TRF2 expression is uncommon during early breast cancer transformation in vivo.
- Increased TRF2 may protect advanced cancer cells with critically short telomeres.
- Cancer cell lines may not fully represent the heterogeneity of authentic tumors.
More Related Videos
Related Concept Videos
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...